Novel Oral Amphotericin B Formulation Shows Promise for Cryptococcal Meningitis

A randomized, controlled trial by Boulware and colleagues demonstrated that a new oral lipid nanocrystal formulation of amphotericin had similar antifungal activity and survival rates but significantly less toxicity compared to intravenous amphotericin when used as induction therapy for human immunodeficiency virus-associated cryptococcal meningitis.